Aspire Biopharma, Inc. Completes Stability Study of Instaprin Test Formulation

HUMACAO, PR, June 21, 2023 – Aspire Biopharma, Inc. (“Aspire” or the “Company”), a developer of disruptive drug delivery mechanism technologies, today announced that as a material part of its Development Agreement and partnership with Glatt Air Techniques, Inc. (“Glatt”), it has successfully completed a six- month the stability and solubility study of its aspirin-based product Instaprin.

Working under the Glatt Pharmaceutical Development Agreement announced in July 2022, Aspire has successfully completed the 3-month and 6-month stability studies of the Company’s first test batch of the Instaprin product. This significant milestone confirms the long-term stability and shelf life of the new aspirin based Instaprin formulation.

Kraig Higginson, Executive Chairman, stated, ”Glatt’s testing of Instaprin continues to demonstrate our belief that Instaprin is a game-changer.”

About Aspire Biopharma, Inc. Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit

About Glatt Air Techniques, Inc. Based in Ramsey, New Jersey, Glatt focuses on product development and manufacturing optimization for granules used in the nutritional, food, feed, pharmaceutical and fine chemicals markets. For more information, please visit

Safe Harbor Statement. Certain information set forth in this news announcement may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Aspire Biopharma, Inc. Such forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management beliefs and certain assumptions made by its management. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Information concerning factors that could cause the Company’s actual results to differ materially from those contained in these forward- looking statements can be found in the Company’s Form CF and Form D, filed with the Securities and Exchange Commission. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether because of new information, future events, or otherwise to reflect future events or circumstances or reflect the occurrence of unanticipated events.